On October 16, 2021 Tyligand Bioscience, a clinical-stage biotechnology company developing innovative small-molecule therapeutics against drug resistant cancers, reported that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for its novel drug TSN084 for treating solid tumors (Press release, Tyligand Bioscience, OCT 16, 2021, View Source [SID1234644990]). TSN084 is a first-in-class multi-kinase inhibitor targeting CDK8/19 and several other kinases implicated in tumorigenesis and immune evasions. The clinical study is about to start at M.D Anderson Cancer Center in the US soon.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Tony Zhang, cofounder and CEO of Tyligand Bioscience, commented, "TSN084 is the front runner of the Tyligand pipeline of molecules designed to treat tumors that become resistant to targeted therapies. We hope the potent activities demonstrated by TSN084 against a unique combination of kinase targets responsible for several major cancer hallmarks in preclinical studies can be translated into clinical outcomes for patients suffering NSCLC and TNBC. FDA’s clearance has moved us one step closer towards achieving that goal！"